Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.
External link for The Center for Biosimilars
Cranbury, NJ 08512, US
The Center for Biosimilars reposted this
Did you miss the #GlobalBiosimilarsWeek webinar on "Streamlining the Regulatory Process to Advance Access to Biosimilars"? Don't worry! You can still watch it in The Center for Biosimilars's Youtube channel here: https://lnkd.in/emq6bzSx
Lung cancer remains the leading cause of cancer-related deaths worldwide. A study was conducted to address the limited real-world data on the clinical efficacy of bevacizumab biosimilars in advanced NSCLC. Read the article below to discover its findings! https://lnkd.in/ecH3zEvA
November's Diabetic Eye Disease Awareness Month comes to a close, but the fight for better vision doesn't! Study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME. https://lnkd.in/dWGSYQCz
Biosimilars Weekly Recap: #5: HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX chemotherapy extended PFS in patients with untreated HER2-positive advanced gastric cancer. #4: Financial incentives introduced by Japan's 2022 health policy resulted in increased use of oncology biosimilars. #3: Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered. #2: The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars. #1: Dr Niazi's latest article proposes the creation of a new association with rational scientific agenda. To read all of these articles: https://lnkd.in/gBGSZeqF
The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and efficacy in treating relapsing multiple sclerosis over 96 weeks. Read on to learn more: https://lnkd.in/eGZhz3pi
This Thanksgiving, the Center for Biosimilars gives thanks for the incredible progress made in the biosimilars landscape! We’re thankful for the opportunity to connect with such a passionate and dedicated community. Thank you to our audience, contributors, and everyone who works tirelessly to advance the field of biosimilars. Let’s continue to innovate and make a difference together.🧡💛🤎
🎵 No one mourns the originators... when biosimilars enter the scene! 🎵 In honor of the #Wicked Part 1 movie release, we’ve brewed up some Oz-some #biosimilar memes inspired by the musical! 🌟 From defying gravity in drug costs to proving they’re popular with providers and patients alike, biosimilars are the true stars of the Emerald City of health care. 💚 ✨ Imagine a world where biosimilars help us say: "I hope you’re happy… because access just got easier!" "It’s time to trust biosimilars and try… defying premiums!" Tag your fellow biosimilar enthusiasts and let’s celebrate innovation that’s changing health care for good! 🎶
The Center for Biosimilars reposted this
Webinar: Streamlining the Regulatory Process to Advance Access to #Biosimilars Unable to make the 2024 #GlobalBiosimilarsWeek webinar, hosted by The Center for Biosimilars and IGBA - International Generic and Biosimilar medicines Association on November 13th? Watch the full event, here: https://lnkd.in/etKehnAX
Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars. Originator biologic companies in the US may respond aggressively to biosimilar competition by significantly increasing rebates—by as much as 89%—and reducing net prices by up to 51%, demonstrating a strong effort to retain market share, according to a recent study. https://lnkd.in/esnzM33s
In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended PFS in untreated HER2-positive advanced gastric cancer patients. https://lnkd.in/eiHbuQPr